Skip to main content
Contact us

Leading CDMO Companies in Netherlands

Your Trusted Partners in the Netherlands for Contract Manufacturing and Development.

Applied Filters:Europe×Clear All
Showing 3 facilities
Bilthoven Biologicals Drug Substance and Drug Product Facilities
Netherlands

Bilthoven Biologicals Drug Substance and Drug Product Facilities

Bilthoven Biologicals BV

Multi-product GMP facilities for Drug Substance and Drug Product.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), MHRA (UK)

BSL (Biological Safety Level): 1, 2

USE: Human

BATCH SIZE: Large, Small, Medium

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

REGION: Europe

CARBOGEN AMCIS | Veenendaal
Netherlands

CARBOGEN AMCIS | Veenendaal

CARBOGEN AMCIS

Large scale manufacturing of Cholesterol and Vitamin D analogs.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: DIGEMID, BRCGS, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), IFS, Halal Research Council, ECOVADIS, TGA (Australia GMP), TITCK (Turkish Health Authorities), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP), SQF (Safe Quality Food), NSF

USE: Human, Veterinary

BSL (Biological Safety Level): 1

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, SERVICES

BATCH SIZE: Small

Limited view

FDF / DRUG PRODUCTS manufacturing site

MAI network supplier

We can take your pharmaceuticals from lab scale to the early clinical phase and beyond.

Location available after registration

Suggested Results

These facilities match your main criteria but not every optional filter — including other countries in the same region.

HISTOCELL S.L. | Cell Therapy, Exosomes & Secretomes
Spain

HISTOCELL S.L. | Cell Therapy, Exosomes & Secretomes

HISTOCELL

Histocell is a Spanish CDMO that develops and manufactures cell therapies, secretomes and exosomes, as well medical devices.

SERVICES: Development services, Analytical / QC services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), CDSCO (India), TGA (Australia)

COMPLIANCE: ISO, EMA (EU GMP)

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: COSMETICS, FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

USE: Human, Veterinary

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism

BATCH SIZE: Small, Medium

REGION: Europe

CARBOGEN AMCIS | Vionnaz
Switzerland

CARBOGEN AMCIS | Vionnaz

CARBOGEN AMCIS

Highly Potent APIs development and small-scale cGMP production including chromatography and lyophilization.

SERVICES: Development services, Analytical / QC services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), CDSCO (India), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)

USE: Human, Veterinary

BATCH SIZE: Small

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

REGION: Europe

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

FAES FARMA | DERIO facility
Spain

FAES FARMA | DERIO facility

FAES FARMA

Developer and manufacturer of human medicinal products.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), EDE (UAE), TGA (Australia)

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human

BATCH SIZE: Large, Small, Medium

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (D) Dermatologicals, (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

REGION: Europe

Laboratorios Grifols | Murcia Plant
Spain

Laboratorios Grifols | Murcia Plant

Grifols International

Sterile manufacturing solutions (small molecules) in flexible bags.

MARKETS: EMA (EU), FDA (USA), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

SERVICES: Logistics, Analytical / QC services, Packaging, Quality Assurance services, Manufacturing services

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

REGION: Europe

Cenexi
France

Cenexi

Cenexi

GMP plant on a four-hectare site is located 9 km east of Paris. It is a center of excellence for injectable ampoules.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), EDE (UAE), TGA (Australia)

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Low potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (D) Dermatologicals, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

REGION: Europe

Nexora Cell and Tissue Therapy Manufacturing Site
Germany

Nexora Cell and Tissue Therapy Manufacturing Site

Green Phoenix Labs GmbH

Licensed ATMP site in Germany. GMP manufacturing and QP batch release for cell and tissue therapies.

SERVICES: Development services, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU)

BSL (Biological Safety Level): 1, 2

USE: Human

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (S) Sensory organs, (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism

BATCH SIZE: Small, Medium

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

REGION: Europe

CARBOGEN AMCIS | Bubendorf
Switzerland

CARBOGEN AMCIS | Bubendorf

CARBOGEN AMCIS

Development and cGMPmanufacturing of Highly Potent API including Antibody Drug Conjugates (ADC).

SERVICES: Development services, Analytical / QC services, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), Turkish Health Authorities, CDSCO (India), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)

USE: Human, Veterinary

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V09-10) Radiopharmaceuticals, (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism

BATCH SIZE: Small, Medium

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CATEGORY / PRODUCT: PARTICLE ENGINEERING, SERVICES, BIOLOGICS, CHEMICAL-SYNTHETIC

REGION: Europe

HIPRA BIOTECH SERVICES | Amer
Spain

HIPRA BIOTECH SERVICES | Amer

HIPRA Biotech Services

End-to-end internal capabilities from cell line development to commercial manufacturing.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BSL (Biological Safety Level): 1, 2

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, BIOLOGICS

REGION: Europe

JAFRAL
Slovenia

JAFRAL

JAFRAL

Integrated biotechnology facility providing R&D, non-GMP and GMP manufacturing, QC testing, and fill & finish services for advanced biologics.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

COMPLIANCE: ICH, FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP), SQF (Safe Quality Food)

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), SFDA (Saudi Arabia), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia)

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: COSMETICS, NUTRACEUTICALS, FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

CONTROLLED SUBSTANCES: Lowest potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use, (D) Dermatologicals, (V06) Nutrients, (R) Respiratory system, (A) Digestive tract and metabolism

REGION: Europe

The Netherlands is a well-established hub for pharmaceutical development and manufacturing within Europe. CDMO companies in the Netherlands are strategically integrated into the global life sciences ecosystem, offering expertise in clinical trial supply, commercial manufacturing, and regulatory support aligned with EMA standards.

From innovative biotech start-ups to global pharmaceutical leaders, companies choose CDMOs in the Netherlands for their compliance with European regulations, advanced infrastructure, and ability to scale efficiently across international markets.

Why Choose CDMOs in the Netherlands?

The Netherlands has built a strong reputation for its advanced pharmaceutical infrastructure and central role in European healthcare systems. CDMOs in the Netherlands benefit from proximity to EMA headquarters in Amsterdam, collaborations with world-class academic and research centers, and access to EU innovation funding programs.

With extensive experience in complex drug development and accelerated EU regulatory pathways, CDMOs in the Netherlands are ideal partners for companies seeking efficient market entry and expansion in Europe.

Key Services Offered by CDMO Companies in the Netherlands

  • Clinical Supply Manufacturing: Phase I–III production with rapid scale-up and EU-wide distribution capabilities.
  • Regulatory & Submission Support: Expertise in EMA submissions, including IMPD and MAA dossiers.
  • High-Containment and Specialty Manufacturing: Facilities equipped for potent APIs, sterile injectables, and complex formulations.
  • Integrated Packaging and Labeling: GMP-compliant packaging with serialization and temperature-controlled logistics for European distribution.
  • Tech Transfer & Commercial Readiness: Seamless transitions from development to launch with validated processes and commercial-scale support.

Advantages of Partnering with CDMOs in the Netherlands

  • Regulatory Alignment: Direct compliance with EMA requirements for faster approvals and smooth audits.
  • Strategic EU Market Access: The Netherlands offers a central location and logistics advantage for pan-European and global distribution.
  • Skilled Workforce: Highly trained professionals in pharma manufacturing, biotechnology, and regulatory sciences.
  • Robust Infrastructure: State-of-the-art facilities designed for innovation, flexibility, and large-scale production.
  • Trusted Collaborations: Strong track record of partnerships with European and international pharma companies.

CDMO Companies in the Netherlands

Some of the leading CDMO companies in the Netherlands include:

  • CARBOGEN AMCIS | Veenendaal: Dutch CDMO specialized in large-scale pharmaceutical manufacturing, focused on Cholesterol and Vitamin D analogs for global drug development. [See CDMO profile]
  • Basic Pharma Manufacturing: Pharma CDMO in the Netherlands offering GMP-compliant facilities, clinical supply manufacturing, and regulatory support from lab scale to early clinical phases. [See CDMO profile]
  • Bilthoven Biologicals Drug Substance and Drug Product Facilities: Multi-product GMP facilities for Drug Substance and Drug Product. [See CDMO profile]

Related Information

Leading CDMO Companies in Europe

Let MAI CDMO Network Help You Find the Right Netherlands CDMO Partner

Navigating the Dutch CDMO landscape requires market knowledge and trusted connections. MAI CDMO helps you identify the most suitable CDMO companies in the Netherlands—with the regulatory expertise, capacity, and technical skills to accelerate your project.

From early clinical batches to commercial scale production, our tailored matchmaking ensures you find a CDMO in the Netherlands that aligns with your objectives and timelines.

Contact MAI CDMO Network today and discover the right CDMO in the Netherlands to support your product journey from lab to launch.